Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Pubching spatial transcriptomics of MDA-MB-231 xenografts

ABSTRACT: Gene expressional analysis with single cell scale by next generation sequencer revealed clonal dissemination in cancer metastasis. To reveal expressional heterogeneity and cell-cell interaction in the primary tumor and the metastasis, we performed transcriptome analysis of micro-tissues dissected from triple negative breast cancer (TNBC) cell line MDA-MB-231 xenograft model by our automated tissue micro-dissection punching technology. This “multiple micro-tissue transcriptome analysis” revealed that there existed three clusters in primary tumor and axillary lymph-node metastasis, two of which were cancer stem cell-like clusters (CD44/MYC-high, HMGA1-high).

ORGANISM(S): Homo sapiens

PROVIDER: GSE184720 | GEO | 2022/04/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Pivotal role of HMGA1 gene signature in highly metastatic breast cancer

2013-12-10 | GSE35525 | GEO

Pivotal role of HMGA1 gene signature in highly metastatic breast cancer

Project description:Analysis of MDA-MB-231 breast cancer cells depleted for High Mobility Group A1 (HMGA1) using siRNA. HMGA1 is involved in invasion and metastasis in breast cancer cells. Results identify the specific transcriptional program induced by HMGA1 in highly metastatic breast cancer cells. MDA-MB-231 cells were transfected with HMGA1-specific siRNA or a control siRNA. Transfections were performed by using Lipofectamin RNAiMAX (Invitrogen) according to the manufacturer's procedure. Seventy-two hours after transfection, samples were processed for total RNA extraction and hybridization on Affymetrix microarrays. Four biological replicas (A, B, C, D) were used for each of the two conditions, for a total of 8 samples.

2013-12-10 | E-GEOD-35525 | biostudies-arrayexpress

HMGA1 and FOXM1 synergistically regulate a common gene network modulating angiogenesis in breast cancer

Project description:One of the factors involved in TNBC aggressiveness is HMGA1, a member of non-histone chromatin proteins. The High mobility group A1 is an architectural transcription factor which, by altering chromatin structure and interacting with transcription factors, can regulate the transcription of several genes. HMGA1 protein is defined as an oncofetal protein as it is highly expressed during the embryogenesis while its expression decreases or is absent in adults, and it is re-expressed in a variety of tumors, including breast cancer. Several works established that, in breast cancer, HMGA1 expression is correlated with high tumor grade and tumor metastasis, resistance to therapies and poor prognosis. The goal of this project is to find out in details, which are the genes that are modulated by HMGA1 in MDA-MB-231 triple negative breast cancer cell line model.

2019-07-29 | GSE129915 | GEO

HMGA1: A master regulator of tumor progression in triple-negative breast cancer cells

Project description:Emerging evidence suggests that tumor cells metastasize by co-opting stem cell transcriptional networks, although the molecular underpinnings of this process are poorly understood. Here, we show for the first time that the high mobility group A1 (HMGA1) gene drives metastatic progression in triple negative breast cancer cells (MDA-MB-231) by reprogramming cancer cells to a stem-like state. We discovered an HMGA1 signature in triple negative breast cancer cells that is highly enriched in embryonic stem cells. Together, these findings indicate that HMGA1 is a master regulator of tumor progression in breast cancer by reprogramming cancer cells through stem cell transcriptional networks. Future studies are needed to determine how to target HMGA1 in therapy. HMGA1 was knocked-down in MDA-MB-231 cells using siRNA as we previously described (Tesfaye A 2007). RNA from three independent knockdown experiements along with 3 control populations were collected by Rneasy miniprep (Qiagen) and analyzed by Affymetrix Human Exon 1.0 ST platform.

2015-02-18 | E-GEOD-45483 | biostudies-arrayexpress

The development of a prediction model using serum microRNAs for evaluating axillary lymph node metastasis in breast cancer

Project description:The combination of serum miRNAs and clinical factors could be a powerful classifier for evaluating axillary lymph node metastasis in breast cancer.

2023-02-13 | GSE110317 | GEO

Proteomic analysis of HMGA1-silencing

Project description:HMGA1 is a well-established oncogene and is a master regulator in breast cancer cells controlling the shift from a non-tumorigenic epithelial-like phenotype towards a highly aggressive mesenchymal-like one. In this work we compared HMGA1-silenced versus control MDA-MB-231 by means of a label free shotgun proteomics approach and crossed these data with DNA microarray expression profile obtained on the same cells. Resulting data were then filtered for genes linked to poor prognosis in breast cancer gene expression meta-datasets. This workflow allows us to establish a small molecular signature composed by 21 members with a prognostic value as regards overall-, recurrence free-, and distant metastasis free-survival in breast cancer.

2018-10-17 | PXD002032 | Pride

Epigenome analysis of primary breast cancer tumors and different types of recurrences.

Project description:Genome wide DNA methylation profiling of primary breast cancer tumors and their axillary metastasis and/or ipsilateral breast recurrence and/or contralateral breast recurrence. The Illumina Infinium 27k Human DNA methylation Beadchip v1.2 was used to obtain DNA methylation profiles across approximately 27,000 CpGs. Samples included 20 primary breast tumors and their matched axillary metastasis, 17 primary breast tumors and their matched ipsilateral breast recurrence, and 11 primary breast tumors and their matched contralateral breast recurrence.

2013-12-24 | GSE44870 | GEO

Epigenome analysis of primary breast cancer tumors and different types of recurrences.

2013-12-24 | E-GEOD-44870 | biostudies-arrayexpress

Circulating Tumor Cell Clusters are Oligoclonal Precursors of Breast Cancer Metastasis

Project description:Clusters of circulating tumor cells (CTC-clusters) are present in the blood of patients with cancer but their contribution to metastasis is not well defined. Here, we first use mouse models to demonstrate that breast cancer cells injected intravascularly as clusters are more prone to survive and colonize the lungs than single cells. Primary mammary tumors comprised of tagged cells give rise to oligoclonal CTC-clusters, with 50-fold increased metastatic potential, compared with single CTCs. Using intravital imaging and in vivo flow cytometry, CTC-clusters are visualized in the tumor circulation, and they demonstrate rapid clearance in peripheral vessels. In patients with breast cancer, presence of CTC-clusters is correlated with decreased progression-free survival. RNA sequencing identifies the cell junction protein plakoglobin as most differentially expressed between clusters and single human breast CTCs. Expression of plakoglobin is required for efficient CTC-cluster formation and breast cancer metastasis in mice, while its expression is associated with diminished metastasis-free survival in breast cancer patients. Together, these observations suggest that plakoglobin-enriched primary tumor cells break off into the vasculature as CTC-clusters, with greatly enhanced metastasis propensity. RNA-seq from 29 samples (15 pools of single CTCs and 14 CTC-clusters) isolated from 10 breast cancer patients

2014-07-11 | E-GEOD-51827 | biostudies-arrayexpress

HMGA1: A master regulator of tumor progression in triple-negative breast cancer cells

2015-02-18 | GSE45483 | GEO